In early pre-clinical tests, RMC-4630 was shown to slow the growth of tumors and kill tumor cells by reducing the signaling from the Ras-Raf-MEK-ERK cascade in human cancers with specific mutations in this pathway [84,85]. The gene discussed is MAP2K7; the disease is neoplasm.